## Systemic Bioavailability of Inhaled Corticosteroids **Key Point:** Ciclesonide is a prodrug that undergoes rapid esterification in the lung to its active metabolite (des-ciclesonide), with minimal systemic absorption of the parent compound. The active metabolite has extremely low oral bioavailability due to extensive first-pass hepatic metabolism. ### Bioavailability Comparison | ICS | Systemic Bioavailability | Mechanism of Low Bioavailability | | --- | --- | --- | | Ciclesonide | <1% (parent drug) | Rapid lung esterification; active metabolite undergoes first-pass metabolism | | Fluticasone propionate | 1–2% | High lipophilicity; poor GI absorption | | Beclomethasone dipropionate | 10–15% | Partial first-pass metabolism | | Mometasone furoate | 2–5% | Moderate first-pass metabolism | **High-Yield:** Ciclesonide's unique prodrug design makes it the ICS with the **lowest systemic exposure**, reducing the risk of HPA axis suppression and systemic adverse effects—particularly important in pediatric populations. **Clinical Pearl:** This property makes ciclesonide an excellent choice for patients requiring high-dose ICS therapy or those at risk for systemic corticosteroid side effects (e.g., children, osteoporosis risk). [cite:KD Tripathi 8e Ch 26]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.